CDSCO flags 2 drugs as spurious, another 111 fail quality test in Nov '24

Q: How long will it take to read this news story?

The story "CDSCO flags 2 drugs as spurious, another 111 fail quality test in Nov &#039;24" has 426 words across 15 sentences, which will take approximately 2 - 4 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "CDSCO flags 2 drugs as spurious, another 111 fail quality test in Nov &#039;24" was covered 18 hours ago by Business Standard, a news publisher based in India.

Q: How trustworthy is 'Business Standard' news outlet?

Business Standard is a fully independent (privately-owned) news outlet established in 1975 that covers mostly business and finance news. The outlet is headquartered in India and publishes an average of 136 news stories per day. It's most recent story was published 2 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #24698864</li><li>URL: https://beamstart.com/news/cdsco-flags-2-drugs-as-17353295036584</li></ul>

Business Standard Logo Business Standard 18h ago

CDSCO flags 2 drugs as spurious, another 111 fail quality test in Nov '24 - Business Standard

Quick Summary:

The list also includes Cipla’s Tofajak tablets, used to treat rheumatoid arthritis, and Intas Pharma’s chest pain medication Monit SR30 tablets.

NSQ drugs are those that do not meet the quality standards set by national or international authorities.

These drugs include batches of fixed-dose combinations (FDCs), such as hypertension medication Ozomet PG2 tablets manufactured by Ozone Pharmaceuticals.